OTCMKTS:FSNUY - Fresenius SE & Co. KGaA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.36
  • Forecasted Upside: -0.27 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$13.40
▼ -0.02 (-0.15%)

This chart shows the closing price for FSNUY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fresenius SE & Co. KGaA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FSNUY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FSNUY

Analyst Price Target is $13.36
▼ -0.27% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Fresenius SE & Co. KGaA in the last 3 months. The average price target is $13.36, with a high forecast of $13.36 and a low forecast of $13.36. The average price target represents a -0.27% upside from the last price of $13.40.

This chart shows the closing price for FSNUY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Fresenius SE & Co. KGaA. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
7/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/23/2021BarclaysSet Price TargetOverweight$13.36
7/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/21/2021Morgan StanleyReiterated RatingOverweight
7/21/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
7/21/2021UBS GroupUpgradeNeutral
5/12/2021DZ BankReiterated RatingBuy
4/28/2021BarclaysReiterated RatingOverweight
2/19/2021Berenberg BankReiterated RatingBuy
2/10/2021JPMorgan Chase & Co.Reiterated RatingOverweight
2/4/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
2/3/2021DZ BankReiterated RatingBuy
2/2/2021BarclaysReiterated RatingOverweight
1/6/2021Nord/LBReiterated RatingBuy
12/3/2020Bank of AmericaDowngradeBuy ➝ Neutral
11/26/2020DZ BankReiterated RatingBuy
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/2/2020Morgan StanleyReiterated RatingOverweight
9/23/2020BarclaysUpgradeEqual Weight ➝ Overweight
8/14/2020JPMorgan Chase & Co.Reiterated RatingOverweight
8/5/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
6/1/2020BarclaysReiterated RatingEqual Weight
5/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
5/19/2020JPMorgan Chase & Co.Reiterated RatingOverweight
4/27/2020BarclaysReiterated RatingEqual Weight
4/23/2020JPMorgan Chase & Co.Reiterated RatingOverweight
3/24/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform
11/12/2019Sanford C. BernsteinInitiated CoverageOutperform ➝ Market Perform
3/22/2019The Goldman Sachs GroupReiterated RatingBuy
3/7/2019Jefferies Financial GroupReiterated RatingHold
1/15/2019BarclaysDowngradeOverweight ➝ Equal Weight
1/9/2019UBS GroupUpgradeSell ➝ Neutral
12/18/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy
11/17/2017UBS GroupDowngradeNeutral ➝ Sell
3/21/2017UBS GroupDowngradeBuy ➝ Hold
(Data available from 7/28/2016 forward)
Fresenius SE & Co. KGaA logo
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Read More

Today's Range

Now: $13.40
Low: $13.34
High: $13.41

50 Day Range

MA: $13.47
Low: $12.92
High: $14.32

52 Week Range

Now: $13.40
Low: $9.17
High: $14.81

Volume

11,268 shs

Average Volume

26,205 shs

Market Capitalization

$29.81 billion

P/E Ratio

15.22

Dividend Yield

1.34%

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Fresenius SE & Co. KGaA?

The following Wall Street research analysts have issued reports on Fresenius SE & Co. KGaA in the last year: Bank of America Co., Barclays PLC, Berenberg Bank, Deutsche Bank Aktiengesellschaft, DZ Bank AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Nord/LB, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for FSNUY.

What is the current price target for Fresenius SE & Co. KGaA?

1 Wall Street analysts have set twelve-month price targets for Fresenius SE & Co. KGaA in the last year. Their average twelve-month price target is $13.36, suggesting a possible downside of 0.3%. Barclays PLC has the highest price target set, predicting FSNUY will reach $13.36 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $13.36 for Fresenius SE & Co. KGaA in the next year.
View the latest price targets for FSNUY.

What is the current consensus analyst rating for Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA currently has 1 sell rating, 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FSNUY will outperform the market and that investors should add to their positions of Fresenius SE & Co. KGaA.
View the latest ratings for FSNUY.

What other companies compete with Fresenius SE & Co. KGaA?

How do I contact Fresenius SE & Co. KGaA's investor relations team?

Fresenius SE & Co. KGaA's physical mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The company's listed phone number is 49-6172-6080 and its investor relations email address is [email protected] The official website for Fresenius SE & Co. KGaA is www.fresenius.com.